Thursday 20 June 2013




The Autoimmunity Research Foundation is a 501(c)3 charity whose educational efforts are focused on helping Health Professionals, and the public, understand the cause of Th1 chronic inflammatory disease.  Many chronic and autoimmune conditions, including Fibromyalgia, RA, MS, Chronic Fatigue Syndrome (CFS/ME), Sarcoidosis, Depression and Bipolar Disorder, are now succumbing to therapies based on our molecular description of inflammatory disease biology.
 

 ..........................................................................................................................................................................................................................

 'Autoimmune' is a name frequently given to diseases characterized by the presence of Th1 inflammation. Patients are still often told there is no known cure, while they are given palliative medications intended to reduce symptoms, without changing the outcome of the disease. Scientists have now identified a common intra-phagocytic bacterial pathogenesis (cause) for much chronic disease, including those thought to be 'autoimmune', and other idiopathic (unknown-cause) conditions including Chronic Fatigue Syndrome, Myalgic Encephalomyelitis, (CFS/ME), Fibromyalgia, Sarcoidosis and Post-Treatment Lyme Disease Syndrome (PTLDS).

There is no way to measure the cost to families who are suffering the ravages of chronic disease. At the core of our logo is a molecule depicting the hope that 21st Century science brings to the elderly, confined to wheelchairs, slowly becoming totally dependent upon their children. Their children, concerned about the future of the entire family, look to the science to find a cure before the pain, suffering, and cost become unbearable.

The Autoimmunity Research Foundation is working with physicians around the world to implement effective therapies based on the new discoveries. The FDA has already granted orphan product designations for two of our eight applications - in the deadly disease Sarcoidosis, and the Foundation continues to work with the FDA to make effective therapies available in a wide range of diagnoses, including Sarcoidosis, Progressive MS, ALS, and PTLDS CFS/ME Fibromyalg

No comments:

Post a Comment